|
 Click here to learn more about our clinical development partner, RRD International, and its management team.
Charles W. Finn, Ph.D., Chief Executive Officer
Dr. Finn is responsible for the overall direction of RRD and the management of RRD’s core development teams. He has more than 20 years of experience in the research, development and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. Dr. Finn began his career as a Staff Fellow at the FDA in the Center for Biologics Evaluation and Research. Subsequently, Dr. Finn held senior positions of increasing responsibility in regulatory affairs and product development with several companies including Lederle-Praxis Biologicals, Miles Pharmaceuticals, Genetics Institute, BRI International, Quintiles and Prestwick Clinical. Dr. Finn has extensive experience in establishing and managing drug development project teams. Dr. Finn earned his Ph.D. in Biology at Georgetown University.
Frank L. Hurley, Ph.D., Chief Scientific Officer
Dr. Hurley has more than 30 years of experience in assisting companies with their regulatory, research, and product development strategies. He has developed deep expertise in clinical trial design and analysis, review of preclinical and clinical information, preparation of regulatory documents and presentations to government regulatory agencies. He is a recognized and published educator and authority on research strategy and study design for pharmaceuticals, biologics and medical devices. Dr. Hurley co-founded BRI International, Inc. in 1971 and guided its growth as both Chairman and Chief Scientific Officer until he merged BRI with Quintiles Transnational, Inc. in 1996, where he served as Chief Scientific Officer until 2001. Dr. Hurley earned a Ph.D. in Biostatistics from the Johns Hopkins University, Bloomberg School of Public Health.
Carolyn R. Pratt, Executive Vice President
Ms. Pratt joined RRD after spending five years in investment banking, most recently with Needham & Co., where she was a Senior Analyst covering the biotech sector and prior to that at Montgomery Securities. Ms. Pratt was at Genetics Institute for seven years, where she worked as a Manager of Business Development and as Product Manager for a novel protein therapeutic. She began her professional career with the Ortho Pharmaceuticals division of Johnson & Johnson, where she worked in clinical research and also in sales, where she participated in the commercial launch of the first FDA approved monoclonal antibody. Ms. Pratt holds a degree in Pharmacy from the University of Rhode Island.
Curtis L. Scribner, M.D., Senior Vice President, Medical and Regulatory Affairs
Dr. Scribner is a board certified physician in internal medicine and has decades of experience running large clinical programs. Dr. Scribner joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer. Previously, he was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous regulatory approval applications. Prior to Quintiles, Dr. Scribner spent ten years at the FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics Evaluation and Research. Dr. Scribner holds an M.D. from the University of Colorado, and an M.B.A. from the University of Maryland.
|
